Emerging molecular, gene, and cell-based therapeutics targeting ocular diseases could prevent and potentially reverse cell degeneration and subsequent vision loss. However, reliable and safe delivery of these therapeutics into targeted ocular layers is an ongoing concern of the FDA, which may affect the advancement of these potentially life-changing new treatments. To increase delivery accuracy, reliability, safety and ease of the new molecular therapeutic procedures, we propose to develop B-scan OCT-guided robotic-assisted subretinal therapeutic delivery techniques.

Published: 17 June 2019